IRS-1 - JC T-antigen Interaction in Cerebellar Tumors

IRS-1 - JC T 抗原在小脑肿瘤中的相互作用

• 批准号: 6464827
• 负责人: Krzysztof Reiss
• 金额: $ 26.79万
• 依托单位: TEMPLE UNIV OF THE COMMONWEALTH
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-03-06 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6464827
• 关键词: Polyomavirus hominis 2; binding sites; biological signal transduction; cell line; chimeric proteins; disease /disorder model; genetically modified animals; genome; growth factor receptors; immunocytochemistry; immunoprecipitation; insulinlike growth factor; intracellular transport; laboratory mouse; medulloblastoma; molecular cloning; neoplastic transformation; pediatric neoplasm /cancer; protein localization; protein protein interaction; protein transport; site directed mutagenesis; tissue /cell culture; tumor antigens

Medulloblastomas represent about 25 percent of all pediatric intracranial neoplasms. These highly malignant tumors arise from the cerebellum and affect mainly children between ages five and fifteen. Although the etiology of medulloblastoma remains unknown, several reports suggest that insulin-like growth factor I (IGF-1) may contribute to the development of these tumors. Our recent studies revealed the presence of the phosphorylated (active) IGF-I receptor (IGF-IR) in more than half of human medulloblastoma biopsies examined. The major IGF-IR signaling molecule, insulin receptor substrate 1 (IRS-1) is strongly overexpressed in these tumors, and the IRS-1 translocation to the nucleus has been observed exclusively in JCV T-antigen positive medulloblastoma cell lines, and in JCV T- antigen positive human medulloblastoma biopsies. A transgenic animal model utilizing the JC virus (JCV) early genome provides an experimental system, in which the IRS-1 could be actually studied in medulloblastomas. These mice develop spontaneous cerebellar tumors that histologically are close parallels to human medulloblastomas. The early genome of this virus encodes regulatory protein, JCV T-antigen, that has transforming properties in cell culture, and is tumorogenic in experimental animals. Interestingly, recent studies revealed association of JCV genome with spontaneous medulloblastomas in humans, and the expression of JCV T-antigen in some but not all human tumor cells. This is comparable with the observation in transgenic mouse model where not all medulloblastoma cells containing JCV early genome, express T-antigen. Although a cause and effect relationship between JCV T-antigen and human medulloblastoma remains to be established, the availability of JCV T-antigen positive and negative medulloblastoma cell lines provides an unique experimental system, in which the role of IRS-1 nuclear translocation could be studied in a different T-antigen context. Three specific aims are proposed to test the hypothesis that IRS- 1 nuclear translocation contributes to the malignant growth in medulloblastoma. In the first aim, mutational analysis of the IRS-1 and JCV T-antigen will be applied to determine binding domains involved in the physical interaction between these two molecules. In the second aim, by targeting IRS-1 and JCV T- antigen binding sites we will develop new dominant negative mutants capable of interfering with the IRS-1- JCV T-antigen binding. These new mutants will be tested in both JCV T-antigen positive and negative medulloblastoma cell lines to determine whether the IRS-1 - JCV T-antigen interaction contributes to the transformed phenotype in medulloblastomas. Finally in the third aim, we will characterize biological significance of the JCV T- antigen -mediated translocalization of IRS-1 into the nucleus, and determine whether targeted disruption of the IRS-1 - JCV T- antigen interaction attenuates the development and/or progression of primitive neuroectodermal tumors/medulloblastomas in experimental animals.

髓母细胞瘤约占所有小儿颅内肿瘤的25％。 这些高度恶性的肿瘤来自小脑，主要影响五至15岁的儿童。 尽管髓母细胞瘤的病因尚不清楚，但一些报告表明，胰岛素样生长因子I（IGF-1）可能有助于这些肿瘤的发展。 我们最近的研究揭示了在检查的一半以上的人类髓母细胞瘤活检中存在磷酸化（活性）IGF-I受体（IGF-IR）。 在这些肿瘤中，主要的IGF-IR信号分子，胰岛素受体底物1（IRS-1）强烈表达，并且在JCV T-抗原阳性髓母细胞系中仅观察到IRS-1转运至细胞核，在JCV T-抗原T-抗原T-抗原阳性人类髓母细胞瘤中。 利用JC病毒（JCV）早期基因组的转基因动物模型提供了一个实验系统，在该系统中实际上可以在髓母细胞瘤中研究IRS-1。 这些小鼠会出现自发的小脑肿瘤，组织学上与人髓母细胞瘤紧密相似。 该病毒的早期基因组编码调节蛋白JCV T-抗原，它在细胞培养中具有转化性质，并且在实验动物中具有肿瘤性。 有趣的是，最近的研究揭示了JCV基因组与人类自发性髓母细胞瘤的关联，以及在某些但不是所有人类肿瘤细胞中JCV T-抗原的表达。 这与转基因小鼠模型中的观察值相当，在转基因小鼠模型中，并非所有含有JCV早期基因组Express T-抗原的髓母细胞细胞。 尽管JCV T-抗原与人髓母细胞瘤之间的因果关系仍有待确定，但JCV T-抗原阳性和阴性髓母细胞瘤细胞系的可用性提供了独特的实验系统，其中IRS-1核易位的作用可以在不同的T-抗原环境中研究。提出了三个特定的目的，以检验IRS-1核易位有助于髓母细胞瘤的恶性增长的假设。 在第一个目标中，将应用对IRS-1和JCV T抗原的突变分析来确定这两个分子之间物理相互作用涉及的结合域。 在第二个目标中，通过靶向IRS-1和JCV T抗原结合位点，我们将开发出能够干扰IRS-1-JCV T抗原结合的新的显性阴性突变体。 这些新突变体将在JCV T抗原阳性和阴性髓母细胞瘤细胞系中进行测试，以确定IRS-1-1-JCV T抗原相互作用是否有助于髓母细胞瘤中转化的表型。 最后，在第三个目标中，我们将表征JCV T抗原介导的IRS-1易位性的生物学意义，并确定靶向破坏IRS-1-JCV T抗原相互作用是否靶向破坏了实验性动物/或者在实验中的原始神经性抑制性肿瘤/或进展。